Transdermal Drug Delivery Systems Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Transdermal Drug Delivery System Market size amassed over USD 29 billion in revenue in 2022. The industry is anticipated to witness over 8% CAGR between 2023 and 2032, owing to a remarkable surge in incidences of chronic ailments.
expenditure on health and boosted investments in R&D projects focused on enhancing medicine and route of administration. For instance, the Centers for Disease Control and Prevention data suggests that chronic diseases are one of the prime drivers of annual healthcare costs of $4.1 trillion in the U.S. These factors, in line with the continuous technological developments in the drug delivery system, will augment market share.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Transdermal Drug Delivery Systems Market size in 2022: | USD 29 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 8 |
| 2023 Value Projection: | USD 61 Billion |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 195 |
| Tables, Charts & Figures: | 334 |
| Segments Covered: | Type, Application, End-use and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
In contrast, the limited number of approved medications and transdermal drug delivery systems worldwide may hamper industry performance. Also, the transdermal treatment route is not considered suitable as it may cause drug irritation or skin sensitivity, hindering the market landscape. Alongside the development, recall, and failure of a transdermal drug delivery system (TDDS) associate high costs, which may further act as a growth restraint over the forecast timeframe.
With respect to type, the transdermal patches segment of the transdermal drug delivery system market is expected to garner over USD 35.5 billion by 2032. Patches are classified into matrix patches, drug-in-adhesive patches, microneedle patches, and reservoir membrane patches. The increasing prevalence of several chronic conditions, such as cardiovascular diseases, cancer, and others, will supplement the market progress.
Transdermal drug delivery system market from the pain management segment is poised to record a valuation of over USD 19.5 billion by 2032. Opioid patches are extensively used in pain management applications, spurring market growth. Furthermore, the increasing prevalence of cancer, resulting in the accelerated embracing of pain patches.
Transdermal drug delivery system market from hospitals segment is likely to emerge as a major consumer of transdermal drug delivery systems, accounting for over USD 17 billion by 2032. A large patient population undergoing treatment for a variety of disorders will accelerate product adoption across hospital settings. Furthermore, the availability of a wide range of medical services in these establishments will transform business dynamics.
North America transdermal drug delivery system market accumulated over 46.% of revenue share in 2022 and is speculated to attain a healthy CAGR through 2032. Growing adoption of unhealthy lifestyles among individuals, such as alcohol consumption, smoking, and lack of exercise, will boost the disease rate, thereby fostering the market trends.
Key players in the transdermal drug delivery system market are:
Companies operating in this business vertical are indulging strategic associations and drug R&D projects to strengthen their market standing.
The COVID-19 pandemic had a damaging impact on the transdermal drug delivery system industry. The stringent lockdown measures implemented by numerous governments worldwide created a huge gap in product demand and supply, thus, resulting in a decline in the sales of transdermal drug delivery systems. Furthermore, reduced patient visits to the hospital due to delays and cancellation of elective medical procedures further limited product uptake, thus, impacting the trade dynamics during the crisis.
By Type
By Application
By End-use
The above information is provided for the following regions and countries:
Pain management segment is estimated to reach over USD 19.5 billion by 2032, driven by the rapid surge in the incidences of cancer worldwide.
Global market for transdermal drug delivery system was worth more than USD 29 billion in 2022 and is poised to exhibit over 8% CAGR during 2023-2032, owing to the mounting burden of chronic health disorders.
Major companies in the transdermal drug delivery system market are Novartis, Mylan, Amneal Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., UCB, Hisamitsu Pharmaceutical Co., Inc., Corium, Inc., Micropoint Technologies, Sparsha Pharma International Pvt. Ltd., and Luye Pharma.
Transdermal patches segment is speculated to be worth over USD 35.5 billion by 2032, given the consistent technological developments in existing drug delivery systems.